Dow Chemical Co. (DOW) Tops Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts DOW Hot Sheet
Price: $30.57 --0%
Financial Fact:
Restructuring charges: 0
Today's EPS Names:
VAXX, NMRD, EGRX, More
Financial Fact:
Restructuring charges: 0
Today's EPS Names:
VAXX, NMRD, EGRX, More
Join SI Premium – FREE
Dow Chemical Co. (NYSE: DOW) reported Q2 EPS of $0.64, $0.01 better than the analyst estimate of $0.63. Revenue for the quarter came in at $14.6 billion versus the consensus estimate of $14.48 billion.
Andrew N. Liveris, Dow's chairman and chief executive officer, stated:
"Our results in the second quarter are indicative of Dow's focus and drive to aggressively manage our portfolio and generate momentum across our enterprise – expanding margins, growing cash flow and increasing earnings, even in the midst of a slow-growth macroeconomic environment. Strong performance in Agricultural Sciences and Performance Plastics clearly demonstrates Dow’s market and technology leadership in those segments. We also are fully implementing aggressive improvement plans in those segments that do not currently meet our return on capital expectations. Our strong cash generation, our deployment of K-Dow proceeds to pay down debt and our ongoing $1.5 billion share buyback program are all focused on rewarding our shareholders – and we will continue to do so as our earnings grow."
For earnings history and earnings-related data on Dow Chemical Co. (DOW) click here.
Andrew N. Liveris, Dow's chairman and chief executive officer, stated:
"Our results in the second quarter are indicative of Dow's focus and drive to aggressively manage our portfolio and generate momentum across our enterprise – expanding margins, growing cash flow and increasing earnings, even in the midst of a slow-growth macroeconomic environment. Strong performance in Agricultural Sciences and Performance Plastics clearly demonstrates Dow’s market and technology leadership in those segments. We also are fully implementing aggressive improvement plans in those segments that do not currently meet our return on capital expectations. Our strong cash generation, our deployment of K-Dow proceeds to pay down debt and our ongoing $1.5 billion share buyback program are all focused on rewarding our shareholders – and we will continue to do so as our earnings grow."
For earnings history and earnings-related data on Dow Chemical Co. (DOW) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
- ADC Therapeutics SA (ADCT) Tops Q2 EPS by 11c
- Cellectar Biosciences (CLRB) Misses Q2 EPS by 9c
Create E-mail Alert Related Categories
Earnings, Management CommentsRelated Entities
Stock Buyback, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
